ilovepablo
Nuovo Utente
- Registrato
- 5/11/12
- Messaggi
- 1.125
- Punti reazioni
- 28
Follow along with the video below to see how to install our site as a web app on your home screen.
Nota: This feature may not be available in some browsers.
Migliora la tua strategia di trading con le preziose intuizioni dei nostri esperti su oro, materie prime, analisi tecnica, criptovalute e molto altro ancora. Iscriviti subito per partecipare gratuitamente allo Swissquote Trading Day.
Per continuare a leggere visita questo LINKBeh, a +200% dovrei assumermi anche io l' onere di andarvi sulle scatoleNel caso, non me ne vogliate
Perché scaricano tutti così?Incommentabile
|
|
grazie The
Immutep Achieves 50% Enrolment Milestone in Randomised Phase IIb
TACTI-003 Trial for First Line Head & Neck Cancer
Immutep has enrolled and randomised over 50% of the planned 154 patients in the TACTI-003 Phase IIb trial.
TACTI-003 is evaluating Immutep’s first-in-class soluble LAG-3 protein eftilagimod alpha (“efti”), in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as 1st line treatment of recurrent or metastatic head and neck squamous cell carcinoma (1L HNSCC).
Marc Voigt, CEO of Immutep stated: “We are pleased to reach this important milestone and extend our sincere appreciation to our investigators, clinical team, partners and most importantly patients who have participated in this study. As clinical evidence showing the compelling benefits of combining efti with immune checkpoint therapies such as pembrolizumab continues to grow, we are increasingly excited about efti’s potential to safely deliver superior clinical outcomes and meaningfully expand the population of cancer patients that respond to treatment.”
https://app.sharelinktechnologies.com/announcement/asx/668470b9f1cf26f3dc37cbd3954715cc
cioè il cambio ti aiuta o ti penalizza?io considerando il cambio sono ancora sotto di più di un 5%
beh ultimamente ha penalizzatocioè il cambio ti aiuta o ti penalizza?